FindTrial
Sign In

LY3537982

DRUG8 trials

Sponsors

Eli Lilly and Company

Conditions

Advanced Solid TumorsBiliary Tract NeoplasmsCarcinoma, Non-Small-Cell LungColorectal NeoplasmsEndometrial NeoplasmsHealthyNeoplasm MetastasisOvarian Neoplasms

Phase 1

Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
Active, not recruitingNCT04956640
Eli Lilly and CompanyBiliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms +3
Start: 2021-07-19End: 2027-04-01Target: 540Updated: 2026-05-29
A Study of the Effect of Food on LY3537982 in Healthy Participants
CompletedNCT05824858
Eli Lilly and CompanyHealthy
Start: 2023-04-12End: 2023-06-17Updated: 2023-09-29
A Study of the Effects of Itraconazole or Carbamazepine on LY3537982 in Healthy Participants
CompletedNCT05860933
Eli Lilly and CompanyHealthy
Start: 2023-05-08End: 2023-08-28Updated: 2024-11-08
A Study of [14C]-LY3537982 in Healthy Participants
CompletedNCT05901311
Eli Lilly and CompanyHealthy
Start: 2023-06-05End: 2023-08-10Updated: 2024-11-08
A Drug-Drug Interaction Study of LY3537982 on Midazolam, Digoxin, and Rosuvastatin in Healthy Participants
CompletedNCT06111521
Eli Lilly and CompanyHealthy
Start: 2023-10-27End: 2024-04-01Updated: 2024-11-08
A Study of LY3537982 in Chinese Participants With Advanced Solid Tumors
CompletedNCT06235983
Eli Lilly and CompanyAdvanced Solid Tumors
Start: 2024-02-29End: 2026-03-30Updated: 2026-05-29
A Study of LY3537982 in Participants With Kidney Problems Compared With Participants With Normal Kidney Function
CompletedNCT07137689
Eli Lilly and CompanyRenal Insufficiency
Start: 2025-08-18End: 2026-04-10Updated: 2026-04-23

Phase 3

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
RecruitingNCT06119581
Eli Lilly and CompanyCarcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
Start: 2023-12-21End: 2031-01-01Target: 1264Updated: 2026-09-08

Related Papers

1L olomorasib plus pembrolizumab +/- chemotherapy in <i>KRAS</i> G12C-mutant NSCLC patients +/- a prior cycle of SOC: Results from LOXO-RAS 20001 and SUNRAY-01.
Journal of Clinical Oncology2026-05-28
First-line (1L) olomorasib + pembrolizumab in patients with <i>KRAS</i> G12C–mutant advanced NSCLC, and PD-L1 expression 0-49%, from the dose optimization cohorts of LOXO-RAS-20001 and SUNRAY-01.
Journal of Clinical Oncology2026-05-28
SUNRAY-01 trial protocol: an innovative study design of olomorasib and pembrolizumab with or without chemotherapy in <i>KRAS</i> G12C NSCLC
Future Oncology2026-04-06
Pan-tumor activity of olomorasib, a next-generation KRAS G12C inhibitor in KRAS G12C-mutant advanced solid tumors: a first-in-human study
Nature Communications2026-03-12
Efficacy and safety of olomorasib, a second-generation KRAS G12C inhibitor, plus cetuximab in <i>KRAS</i> G12C-mutant advanced colorectal cancer.
Journal of Clinical Oncology2025-05-283 citations
Safety and efficacy of olomorasib + immunotherapy in first-line treatment of patients with <i>KRAS</i> G12C-mutant advanced NSCLC: Update from the LOXO-RAS-20001 trial.
Journal of Clinical Oncology2025-05-282 citations
Abstract CT042: Impact of food on the pharmacokinetics of olomorasib in healthy participants
Cancer Research2025-04-25
Efficacy and safety of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in combination with pembrolizumab in patients with <i>KRAS</i> G12C-mutant advanced NSCLC.
Journal of Clinical Oncology2024-08-102 citations
SUNRAY-01, a pivotal, global study of olomorasib (LY3537982) in combination with pembrolizumab with or without chemotherapy for 1L treatment in <i>KRAS</i> G12C-mutant advanced NSCLC.
Journal of Clinical Oncology2024-08-10
Pan-tumor activity of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in patients with <i>KRAS</i> G12C-mutant advanced solid tumors.
Journal of Clinical Oncology2024-06-0134 citations
Efficacy and safety of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in combination with pembrolizumab in patients with <i>KRAS</i> G12C-mutant advanced NSCLC.
Journal of Clinical Oncology2024-06-0131 citations
SUNRAY-01, a pivotal, global study of olomorasib (LY3537982) in combination with pembrolizumab with or without chemotherapy for 1L treatment in <i>KRAS</i> G12C-mutant advanced NSCLC.
Journal of Clinical Oncology2024-06-018 citations
Efficacy and safety of LY3537982, a potent and highly selective KRAS G12C inhibitor in KRAS G12C-mutant GI cancers: Results from a phase 1 study.
Journal of Clinical Oncology2024-01-2027 citations
Abstract CT028: A first-in-human phase 1 study of LY3537982, a highly selective and potent KRAS G12C inhibitor in patients with KRAS G12C-mutant advanced solid tumors
Cancer Research2023-04-1436 citations
Abstract CT202: A first-in-human phase 1 study of LY3537982, a novel, highly selective and potent KRAS G12C inhibitor in patients with KRAS G12C mutant advanced solid tumors (trial in progress)
Cancer Research2022-06-152 citations